Direct exposure examines how cells or tissues respond to the material itself, while extract-based testing evaluates substances released from the material under defined conditions. Using these approaches can help distinguish effects associated with the physical presence of a device from effects associated with its soluble components, supporting more focused investigation of potential hazards.
Cell viability indicates whether exposure harms living cells, whereas inflammation, irritation, sensitization, and systemic toxicity reveal broader biological responses. Considering several endpoints provides a more complete assessment than relying on a single measurement. The resulting profile can show whether a material presents localized concerns, immune-related effects, or risks that extend beyond the exposure site.
These models provide different levels of biological information. Cell studies can identify responses in a controlled setting, tissue exposure can examine effects in organized living structures, and animal models can assess responses within a whole organism. Defined conditions make comparisons more meaningful and help connect a material’s properties with specific biological outcomes.
The material and its surface design can influence how living systems respond during testing. Evaluating these features alongside endpoints such as viability, inflammation, or irritation helps bioengineers identify relationships between design choices and adverse responses. This information can guide refinement of a biomaterial or device before it advances toward clinical evaluation.
A typical workflow exposes cells, tissues, or animal models to the material or its extracts under defined conditions, measures selected biological responses, and interprets the findings in relation to the intended device or biomaterial. Results can then inform material selection and surface design, while also contributing evidence for safety assessment and regulatory evaluation.
The approach supports development of implants, prostheses, tissue-engineered constructs, and drug-delivery systems. For each application, testing can reveal whether the selected material produces unacceptable local or systemic responses and can help compare design options. Its findings support safer device development by informing decisions before clinical use and contributing to regulatory review.